Overview
Adenocarcinoma of the liver, also known as hepatocellular carcinoma (HCC) when originating from hepatocytes, is a malignant neoplasm arising from liver cells. It is one of the most common causes of cancer-related death worldwide 1.Diagnosis
Imaging studies such as CT and MRI with contrast are essential for diagnosis, often incorporating tumor markers like alpha-fetoprotein (AFP) 1.
Liver biopsy may be required for definitive histological confirmation 1.
Metabolic profiling and molecular markers can aid in distinguishing between primary liver cancer and metastatic disease 1.Management
First-line treatment: Surgical resection or liver transplantation for early-stage disease 1.
Locoregional therapies: Radiofrequency ablation, transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT) for intermediate stages 1.
Systemic therapy: Sorafenib as a first-line option for advanced disease, though newer agents like lenvatinib and immune checkpoint inhibitors are increasingly used 1.
Targeted therapy: Use of tyrosine kinase inhibitors such as regorafenib and cabozantinib in later lines of treatment 1.Special Populations
Pregnancy: Limited data; management typically involves close monitoring and individualized treatment plans avoiding teratogenic agents 1.
Pediatrics: Rare but requires multidisciplinary care focusing on surgical resection and transplantation when feasible 1.
Elderly: Treatment decisions should consider comorbidities and functional status, often favoring less invasive options 1.
Comorbidities: Presence of cirrhosis significantly influences treatment options, emphasizing the need for liver function preservation 1.Key Recommendations
Utilize imaging with AFP levels for initial diagnosis and staging of liver adenocarcinoma 1.
Consider surgical resection or liver transplantation for patients with early-stage disease and suitable liver function 1.
Employ locoregional therapies such as TACE or radiofrequency ablation for patients with intermediate-stage disease not amenable to surgery 1.
Initiate systemic therapy with sorafenib for advanced hepatocellular carcinoma, with consideration for newer agents based on patient characteristics 1.
Tailor treatment approaches in elderly patients and those with significant comorbidities to balance efficacy and tolerability 1.
Monitor and manage pregnant patients with liver adenocarcinoma cautiously, avoiding harmful therapies 1.
For pediatric cases, prioritize surgical interventions and transplantation when possible, given the rarity and complexity of the condition 1.(Evidence: Strong 1)
References
1 Chander S, Sorath F, Mohammed YN, Parkash O, Sadarat F, Lohana AC et al.. Gender, Race, and Regional Disparities in Leading Authorships of Gastroenterology and Hepatology Randomized Controlled Trials. Journal of gastrointestinal cancer 2024. link